Answers are grounded in this paper and cite their sources.
Investigates digital twin frameworks optimizing commercial outcomes in pharmaceutical development, indicating significant advancements in forecasting and decision-making.
This study investigated the application of digital twin frameworks to pharmaceutical product lifecycle management (PLM) with the objective of improving forecasting accuracy, regulatory readiness, and commercial decision-making across clinical, regulatory, and market domains. A modular digital twin architecture was developed to represent pharmaceutical products as dynamic, state-dependent systems integrating clinical performance indicators, regulatory progression variables, and market response signals within a unified simulation environment. Using coupled state-space modeling, Monte Carlo simulation, and sensitivity analysis, the framework evaluated lifecycle trajectories under alternative strategic scenarios, including regulatory delays, clinical failure probabilities, pricing adjustments, and competitive entry dynamics. Comparative analysis against conventional PLM approaches demonstrated substantial reductions in forecast error, decision latency, and lifecycle value volatility, particularly during regulatory review and post-market phases. The digital twin framework attenuated regulatory and clinical risk exposure by enabling early detection of high-impact uncertainties and proactive mitigation through adaptive evidence-generation and commercialization strategies. Commercial optimization outcomes showed consistent improvements in pricing realization, launch timing, market access sequencing, and portfolio reallocation, resulting in higher risk-adjusted net present value across lifecycle phases. The findings confirmed that integrated lifecycle simulation transforms commercialization from a downstream, reactive process into a continuous, data-driven optimization function. Overall, the study established digital twins as strategic decision infrastructures capable of synchronizing scientific, regulatory, and commercial objectives, offering a scalable approach to managing complexity and uncertainty in modern pharmaceutical development and commercialization. Keywords: Digital Twins; Pharmaceutical Product Lifecycle Management; Regulatory Simulation; Clinical Dynamics Modeling; Commercial Optimization. Title: Digital Twins for Pharmaceutical Product Lifecycle Management: Simulating Market, Regulatory, and Clinical Dynamics for Commercial Optimization Author: Ezichi Adanna Anokwuru, Joy Onma Enyejo International Journal of Recent Research in Interdisciplinary Sciences (IJRRIS) ISSN 2350-1049 Vol. 13, Issue 1, January 2026 - March 2026 Page No: 27-41 Paper Publications Website: www.paperpublications.org Published Date: 31-January-2026 DOI: https://doi.org/10.5281/zenodo.18440994 Paper Download Link (Source) https://www.paperpublications.org/upload/book/Digital%20Twins%20for%20Pharmaceutical%20Product-31012026-3.pdf
No takes yet. Share an insight, caveat, or question.
Anokwuru et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: